Xavier Bosch

Publicacions destacades

• Myocardial Protection During Cardiotoxic Chemotherapy

  Autors:

  Witteles RM; Bosch X ;

  Referència: Circulation 2015.

• Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted t

  Autors:

  Bosch, Xavier; Rovira, Montserrat; Sitges, Marta; Domenech, Ariadna; Ortiz-Perez, Jose T;

  de Caralt, Teresa M; Morales-Ruiz, Manuel; Perea, Rosario J; Monzo, Mariano; Esteve, Jordi.

  Referència: Journal Of The American College Of Cardiology 2013.

• The Primary Percutaneous Coronary Intervention Program in Catalonia

  Autors:

  Bosch X; Curós A; Argimon J; Faixedas M; Figueras J;

  Fabrega F; Masia R; Mauri J; Tresserras R.

  Referència: Revista Española De Cardiología. 2011.

• Randomized comparison between clinical evaluation plus N-terminal pro-B-type natriuretic peptide versus exercise testing for decision making in acute chest pain of uncertain origin

  Autors:

  Sanchis, Juan; Bosch, Xavier; Bodi, Vicente; Nunez, Julio; Doltra, Ada;

  (...)

  Santas, Enrique; Bragulat, Ernest; Garcia-Alvarez, Ana; Carratala, Arturo; Llacer, Angel;.

  Veure llistat complet d'autors

  Referència: American Heart Journal 2010.

• Combination of clinical risk profile, early exercise testing and circulating biomarkers for evaluation of patients with acute chest pain without ST-segment deviation or troponin elevation

  Autors:

  Sanchis J; Bosch X; Bodí V; Bellera N; Núñez J;

  Benito B; Ordóñez J; Consuegra L; Heras M; Llàcer A.

  Referència: Heart 2008.

• Causes of ineligibility in randomized controlled trials and long-term mortality in patients with non-ST-segment elevation acute coronary syndromes

  Autors:

  Bosch, Xavier; Delgado, Victoria; Verbal, Fernando; Borquez, Emiliano; Loma-Osorio, Pablo;

  Diez-Aja, Salvador; Miranda-Guardiola, Faustino; Sanchis, Juan.

  Referència: International Journal Of Cardiology 2008.

• Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.

  Autors:

  Bosch X; Marrugat J;

  Referència: Cochrane Database Syst Rev 2001.